EUCTR2010-020892-22-IT进行中（未招募）不适用
A Long-term Extension Study to Assess the Safety and Efficacy of Fostamatinib Disodium (FosD) in the Treatment of Rheumatoid Arthritis - OSKIRA-X
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- ASTRAZENECA
- 入组人数
- 2,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •For inclusion in the study patients must fulfil the following criteria. 1. Provision of informed consent, prior to any study-specific procedures. 2. Patients who have successfully completed a qualifying study (ie, Studies D4300C00001, D4300C00002, D4300C00003 or D4300C00004) with FosD. Or Patients who have participated in a qualifying study and who have been classified as non-responders due to pre-defined lack of efficacy at Week 12 (D4300C00001, D4300C00002, D4300C00003) or Week 6 (D4300C00004).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients must not enter the study if any of the following exclusion criteria are fulfilled: 1. Premature withdrawal from the qualifying study. 2. Development of any of the withdrawal criteria from the qualifying study, including: ? Any physical symptoms of hepatotoxicity. ? Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) or bilirubin rise to a value =5 x upper limit of normal (ULN) at any time. ? AST or ALT rises to a value >3 x ULN accompanied by an elevation of total bilirubin >2 x ULN. ? ALT or AST rises to >3 x ULN with the appearance of worsening fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash or eosinophilia. ? Persistent uncontrolled hypertension despite treatment/dose adjustment (as defined in Appendix F). ? Persistent or recurrent gastrointestinal (GI) intolerance or dizziness despite dose reduction. ? Significant infection. ? Cancer: any malignant lesion. 3. Females who are pregnant or lactating. 4. Any other clinically significant disease or disorder, which in the opinion of the investigator (by its nature or by being inadequately controlled) might put the patient at risk due to participation in the study, or may influence the results of the study, or the patient’s ability to participate in the study.
研究者
相似试验
进行中（未招募）
1 期
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA) (OSKIRA-X)MedDRA version: 16.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2010-020892-22-BEAstraZeneca AB2,000
进行中（未招募）
不适用
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA) (OSKIRA-X)MedDRA version: 14.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2010-020892-22-LTAstraZeneca AB2,000
进行中（未招募）
不适用
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in theTreatment of Rheumatoid Arthritis (RA) (OSKIRA-X)Rheumatoid ArthritisEUCTR2010-020892-22-DEAstraZeneca AB2,000
进行中（未招募）
不适用
A Long-term Extension Study to Assess the Safety and Efficacy of Fostamatinib Disodium (FosD) in the Treatment of Rheumatoid Arthritis - OSKIRA - XMedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2010-020892-22-PTAstraZeneca AB2,000
进行中（未招募）
不适用
A Long-term Extension Study to Assess the Safety and Efficacy of Fostamatinib Disodium (FosD) in the Treatment of Rheumatoid Arthritis - OSKIRA - XMedDRA version: 12.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisRheumatoid ArthritisEUCTR2010-020892-22-HUAstraZeneca AB2,000